Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Singulex to Seek FDA Clearance for Sgx Clarity; Aims for Point-of-Care Prototype by Year End

Singulex to Seek FDA Clearance for Sgx Clarity; Aims for Point-of-Care Prototype by Year End

Jan 20, 2017
|
Monica Heger
Premium

NEW YORK (GenomeWeb) – Singulex plans to list its single-molecule counting Sgx Clarity instrument as a CE-marked in vitro diagnostic in Europe at the end of March and plans to submit it for US Food and Drug Administration clearance in the second half of the year, according to Singulex CEO Guido Baechler.

In an interview at the recent JP Morgan Healthcare conference in San Francisco, Baechler provided an update on the firm's activities in the immunodiagnostics space and in developing its single-molecule counting (SMC) technology for various applications.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

  3. Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

  4. Bio-Techne, Qiagen Expand Partnership on Exosome Technology

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.